// App-Quantinova.ai

552 : Use of a high-sensitivity anti-Mullerian hormone (AMH) assay to determine ovarian function after chemotherapy for early breast cancer.

Researchers

Presenter

  • Florian Clatot

Principal Investigators

  • Kelsey Thomas

  • Matteo Lambertini

  • Nathalie Olympios

  • Orianne Duhamel

  • Anne Perdrix

  • Richard Anderson

Medical Centers

  • INSERM U1245, IRON Group, Centre Henri Becquerel, University Hospital, University of Normandy, Rouen, France

  • School of Computer Science, St Andrews University, St Andrews, United Kingdom

  • Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genoa, Genoa, Italy

  • CRLCC Henri Becquerel, Rouen, France

  • Department of Medical Oncology, Centre Henri Becquerel, Rouen, France

  • Department of Bio-Pathology,IRON group, Centre Henri Becquerel, Rouen, France

  • MRC Centre for Reproductive Health, University of Edinburgh, Edinburgh, United Kingdom

Locations

  • France

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Anti-Müllerian hormone

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Tamoxifen

  • taxane

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved